Concepedia

Concept

rheumatoid arthritis

Parents

54.5K

Publications

2.9M

Citations

168.4K

Authors

13.6K

Institutions

Table of Contents

Overview

Definition and Symptoms

(RA) is a chronic characterized by the immune system's attack on its own tissues, particularly affecting the joints and potentially other internal organs. This condition leads to , pain, swelling, and stiffness, primarily in the joints of the hands, wrists, feet, ankles, knees, shoulders, and elbows.[4.1] RA is systemic in , meaning it can impact multiple body systems, but it predominantly manifests in the joints, causing significant discomfort and loss of function.[6.1] The symptoms of rheumatoid arthritis can vary widely among individuals. Early signs often include fatigue, low-grade fever, and weight loss, alongside joint-related symptoms such as morning stiffness and pain, particularly in the small joints of the hands and feet.[26.1] As the disease progresses, joint swelling becomes more pronounced, and individuals may experience additional symptoms such as malaise and a general feeling of unwellness.[24.1] Unlike , where pain typically correlates with , RA can cause pain even at rest, highlighting the distinct nature of its symptoms.[22.1] and treatment are crucial to manage symptoms effectively and prevent joint damage.[5.1]

History

Discovery and Early Treatments

The of rheumatoid arthritis (RA) dates back hundreds of years, with significant developments occurring in the 19th century. physicians were among the first to study the condition that would later be known as RA, exploring its characteristics and attempting early treatments such as cold therapy and hot water baths.[44.1] The term "rheumatoid arthritis" itself was introduced by Alfred Baring Garrod in 1858, replacing older terms like deformans and rheumatic gout.[46.1] This nomenclature marked a pivotal moment in the understanding of the disease, as it helped to distinguish RA from other forms of arthritis. The recognition of RA as a distinct medical condition was further solidified by Garrod's work, which suggested that the disease was evolving and might even disappear in the future.[46.1] Prior to Garrod's contributions, descriptions of conditions resembling RA can be traced back to ancient texts, such as the Ebers Papyrus from around 1500 BC, which documented symptoms akin to those of rheumatoid arthritis.[51.1] In terms of treatment, historical approaches included methods such as bloodletting and leeching, which were common practices in earlier medical traditions.[60.1] Additionally, was developed in the Far East as a treatment modality for various ailments, including arthritis.[60.1] The understanding of RA's has evolved significantly over time, leading to more effective treatments. For instance, the introduction of cortisone in 1949 revolutionized the of RA, providing a powerful option that garnered widespread .[61.1] By the 1950s and 60s, the use of older forms of medications at lower doses became common for treating RA, paving the way for the development of newer formulations that have been integral to RA management for decades.[62.1]

Evolution of Treatment Approaches

The evolution of treatment approaches for rheumatoid arthritis (RA) has been significantly influenced by advancements in the understanding of the disease. Early treatments in the 19th century included methods such as cold therapy and hot water baths, as physicians sought to alleviate the symptoms of joint inflammation that resembled , an old medical term for joint pain and swelling.[64.1] As the understanding of RA progressed, particularly with the introduction of the term "rheumatoid arthritis" by Sir Alfred Baring Garrod in 1858, treatment began to evolve.[57.1] The classification criteria for RA have undergone substantial changes since the 1950s, with the 1987 revised criteria improving the performance and confidence in correct classification compared to earlier versions.[49.1] This evolution in classification has facilitated the development of targeted therapies and early, aggressive management approaches, which have become increasingly important in the treatment of RA.[49.1] The 2010 ACR/EULAR classification criteria further refined the of RA, particularly in patients with undifferentiated inflammatory synovitis, thereby enhancing and treatment outcomes.[50.1] Research has also revealed that RA-related and inflammation can be present long before the clinical onset of inflammatory arthritis, during a phase termed pre-RA.[67.1] This understanding has prompted a shift towards preventive strategies aimed at identifying and targeting these early phases of RA development, potentially altering the course of the disease.[66.1] Consequently, the evolution of treatment approaches has transitioned from merely managing symptoms to a more proactive stance that emphasizes early intervention and prevention of .

In this section:

Sources:

Recent Advancements

Novel Treatment Options

Recent advancements in the treatment of rheumatoid arthritis (RA) have introduced novel therapeutic options that significantly improve patient outcomes. The development of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs), such as Janus kinase (JAK) inhibitors, has transformed the management of RA. These therapies have made clinical remission a realistic goal for the majority of patients, facilitating the prevention of joint damage and physical dysfunction.[92.1] Biologic therapies specifically target components of the immune system, such as and T cells, which play critical roles in the inflammatory process associated with RA. This targeted approach has been shown to effectively prevent the chronic destruction of synovial and other tissues caused by the disease.[88.1] For instance, the chimeric anti-CD20 monoclonal antibody rituximab and the CTLA4-IgG1Fc protein abatacept have been integrated into , particularly for patients who do not respond adequately to tumor necrosis factor (TNF) inhibitors.[91.1] Recent have demonstrated that JAK inhibitors exhibit more robust and rapid clinical and structural effects compared to placebo, particularly in patients who are naive to methotrexate (MTX) or have had inadequate responses to conventional synthetic DMARDs (csDMARDs) and bDMARDs.[92.1] The efficacy and of these treatments have been further validated through phase III trials, underscoring their role in modern RA management.[92.1] Moreover, the advent of biologic therapies has been associated with significant improvements in patient outcomes, including symptom relief, functional improvement, and a reduction in joint damage.[90.1] These advancements reflect a deeper understanding of RA and a more targeted approach to treatment, which has ultimately enhanced the for many patients.[90.1] However, challenges remain in terms of and affordability of these therapies, which can impact their widespread adoption in clinical practice.[91.1]

Emerging Research and Future Directions

The advent of biologic therapies has significantly transformed the management of rheumatoid arthritis (RA) by targeting specific components of the immune system, such as cytokines and T cells. Unlike traditional disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs specifically inhibit immune system cells or proteins involved in the inflammatory process, thereby preventing chronic destruction of synovial and other tissues associated with RA.[120.1] This shift towards biologic therapies has opened new avenues for , which aims to tailor treatment strategies based on the individual characteristics of patients. To effectively implement personalized medicine in RA, it is essential to characterize the clinical and of patients thoroughly. Identifying subgroups of patients who exhibit either favorable or poor treatment outcomes is a crucial step in this process.[109.1] Recent advancements in methodologies have led to the discovery of promising that can predict treatment responses, thereby enhancing the personalization of .[110.1] Furthermore, pharmacogenetic and studies are instrumental in determining the profiles of patients, which may facilitate more tailored .[111.1] Despite these advancements, challenges remain in the pursuit of personalized medicine for RA. Many studies analyzing treatment response markers are small and retrospective, which limits their applicability.[112.1] Additionally, obstacles such as an incomplete understanding of disease pathogenesis, the need for changes in physician behavior, and the acceptance of costs by health insurers hinder the widespread implementation of personalized strategies.[112.1] Emerging research continues to identify new molecular targets for biologic DMARDs and targeted synthetic DMARDs (tsDMARDs), such as Janus kinase (JAK) inhibitors. These developments not only enhance the efficacy of treatments but also pave the way for more personalized therapeutic options.[121.1] The integration of these targeted therapies into clinical practice aims to achieve clinical remission for the majority of RA patients, thereby preventing joint damage and physical dysfunction.[119.1] Ultimately, the future of RA treatment envisions a truly personalized approach that incorporates individual genetic, environmental, and factors, thereby improving for patients.[122.1] As research progresses, the ability to distinguish RA patients at the level using methods may further refine strategies.[123.1]

In this section:

Sources:

Diagnosis

Diagnostic Criteria

The diagnosis of rheumatoid arthritis (RA) is primarily based on specific classification criteria that guide clinicians in distinguishing RA from other conditions. A rheumatologist evaluates the patient's medical and family history, clinical symptoms, and laboratory results to reach a diagnosis. The presence of specific antibodies, such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (anti-CCP), plays a crucial role in differentiating between seropositive and seronegative RA. A positive test for these antibodies, particularly anti-CCP, which has a specificity of 90-97%, is indicative of seropositive RA, while their absence may lead to a diagnosis of seronegative RA [124.1]. In 2010, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) introduced updated classification criteria to enhance diagnostic accuracy. These criteria employ a weighted scoring system across four domains: joint distribution, serology, acute phase response, and symptom duration. This structured approach is particularly beneficial for diagnosing early inflammatory arthritis, achieving approximately 80.9% accuracy when all criteria are met [135.1]. The criteria not only aid in identifying "definite RA" but also support timely therapeutic interventions, which are crucial for optimal long-term outcomes [134.1]. While serological tests are integral to the diagnostic process, the clinical presentation of RA can vary widely, necessitating a comprehensive evaluation. The updated criteria facilitate a more precise diagnosis, allowing for the early initiation of treatment, which is essential for managing the disease effectively [141.1].

Diagnostic Tools and Procedures

Diagnosing rheumatoid arthritis (RA) involves a combination of clinical evaluation, laboratory tests, and imaging studies. The complexity of the disease, particularly in its early stages, presents significant challenges for clinicians. Early diagnosis is crucial as it can significantly alter the disease's progression and improve patient outcomes. Clinicians utilize various to confirm RA, including serological tests for biomarkers such as rheumatoid factor (RF) and anti-cyclic citrullinated (anti-CCP) antibodies. RF is one of the most widely used biomarkers for establishing an RA diagnosis; however, it is important to note that a does not rule out the disease, and positive results can occur in other autoimmune conditions.[163.1] Additionally, the erythrocyte rate (ESR) and C-reactive protein (CRP) levels are commonly measured to assess inflammation.[160.1] Emerging biomarkers, such as the multi- disease activity (MBDA) score, are also being investigated for their potential to enhance diagnostic accuracy and predict treatment responses.[161.1] Despite the availability of these tests, diagnosing RA can be tricky, especially in its early stages when symptoms may be nonspecific or mild. Patients often face challenges in accessing healthcare services and adhering to prescribed treatments, which can undermine early diagnosis efforts.[136.1] Furthermore, the has exacerbated these issues, leading to increased reluctance among patients to seek care.[136.1] plays a vital role in the diagnostic journey for RA. Interventions aimed at educating patients about their condition can lead to improved health outcomes, including better management of pain and functional .[155.1] Tools such as the Educational Needs Assessment Tool (ENAT) allow patients to prioritize their educational needs, thereby empowering them to communicate their symptoms more effectively to healthcare providers.[156.1] efforts, such as those led by organizations like the Arthritis Foundation, also contribute to improving and access to necessary treatments.[158.1]

In this section:

Sources:

Treatment Options

Medications

Rheumatoid arthritis (RA) treatment has evolved significantly over the past two decades, primarily due to the introduction of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).[164.1] These advancements have transformed the management of RA, allowing for more effective control of inflammation and joint damage.[167.1] The treatment regimen for RA typically includes a combination of medications tailored to the severity of the disease and the individual patient's needs. Commonly prescribed medications include nonsteroidal anti-inflammatory drugs (NSAIDs), which can be used alone or in conjunction with other treatments.[166.1] Among the bDMARDs, tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol have been pivotal in improving patient outcomes.[166.1] Additionally, other biological agents targeting interleukins, such as tocilizumab and sarilumab, have also been utilized in RA management.[166.1] Despite the effectiveness of these therapies, RA remains a chronic condition with no definitive cure, necessitating ongoing treatment and management strategies.[168.1] The choice of medication is influenced by various factors, including the patient's disease activity, the presence of erosions, and autoantibody positivity, which serve as prognostic indicators.[178.1] Furthermore, emerging therapies, including novel biologics and , are currently under investigation, promising to further enhance treatment options for RA in the future.[176.1] In addition to pharmacological treatments, , physical activity, and complementary therapies such as massage can play a crucial role in managing symptoms and improving the quality of life for individuals with RA.[165.1] Overall, the landscape of RA treatment is continuously evolving, with a focus on personalized medicine to optimize therapeutic outcomes for patients.

Non-Pharmacological Approaches

Non-pharmacological approaches to managing rheumatoid arthritis (RA) encompass a variety of strategies aimed at improving patient outcomes and enhancing quality of life. One significant aspect of these approaches is the incorporation of , which can lead to improved physical function, increased independence, and a better overall quality of life for individuals with RA. Physical therapists tailor treatment plans to the unique needs of each patient, integrating periods of activity and rest to optimize outcomes.[171.1] Exercise therapy is a cornerstone of physical therapy for RA, involving several types of exercises designed to maintain or improve joint function. These include range of motion exercises to enhance flexibility, strengthening exercises to support the muscles around the joints, and aerobic activities such as swimming and cycling to boost cardiovascular health.[172.1] In addition to physical therapy, play a crucial role in managing RA. Diet modifications, particularly the adoption of the Mediterranean diet and the inclusion of , have been shown to improve disease outcomes and reduce symptoms.[183.1] Regular physical activity, weight management, and other healthy lifestyle choices are also recommended to help mitigate the effects of the disease.[182.1] Holistic approaches that incorporate practices such as , social connectedness, and positive can further enhance the effectiveness of conventional treatments for RA. These strategies not only address physical symptoms but also contribute to emotional .[186.1] Moreover, the role of patient education and support networks cannot be overstated. Effective patient education goes beyond mere information dissemination; it involves structured activities and psychosocial support that empower patients to manage their condition actively.[191.1] Collaborative goal-setting between patients and healthcare providers has been linked to improved patient experiences and outcomes, emphasizing the importance of alignment in treatment objectives.[190.1] Finally, social support networks, including family, friends, and healthcare professionals, are vital in helping patients cope with the challenges of RA. These networks can buffer disease-related distress and significantly enhance the quality of life for individuals living with this chronic condition.[202.1]

Living With Rheumatoid Arthritis

Self-Management Strategies

Living with rheumatoid arthritis (RA) necessitates the implementation of effective strategies to cope with the physical and emotional challenges associated with the condition. One of the primary strategies involves engaging in regular exercise, which has been shown to alleviate symptoms such as pain and joint stiffness. Exercise can enhance overall health, improve joint function, and boost energy levels, although it may be difficult to initiate due to RA-related pain. It is recommended that individuals with RA incorporate low-impact activities, such as walking and water exercises, into their routines to promote aerobic conditioning and joint health while minimizing discomfort.[223.1] In addition to physical activity, managing is crucial for those living with RA. The interplay between mental and physical health is significant, as and lifestyle changes can lead to increased anxiety, , and stress.[227.1] Engaging with mental health professionals who specialize in chronic illness can provide personalized support and coping strategies to address these emotional challenges.[225.1] Furthermore, is a common issue for individuals with RA, often exacerbated by discomfort and fatigue, which can lead to withdrawal from social activities. This isolation can negatively impact mental health, making it essential to maintain social connections and seek support from the RA community.[228.1]

Support Systems and Resources

Support systems and resources play a crucial role in enhancing the well-being and treatment outcomes for individuals living with rheumatoid arthritis (RA). Community support and advocacy have been shown to significantly influence the overall health of RA patients. For instance, raising awareness about RA can foster , improve patient outcomes, and encourage research and support initiatives, ultimately leading to better access to treatment and policy changes that benefit patients.[216.1] The establishment of patient advocacy groups over the past two decades has been pivotal in promoting arthritis awareness and providing a platform for patients to share their experiences.[215.1] These groups not only facilitate personal advocacy but also contribute to collective efforts aimed at influencing and healthcare access for those affected by autoimmune and autoinflammatory arthritis.[217.1] Support groups, such as the Healing Rheumatoid Arthritis Naturally Support Group on Facebook, offer valuable resources and advice on alternative healing methods, including diet and .[218.1] Additionally, organizations like the Arthritis Foundation provide extensive resources for RA patients, including opportunities for community connection, on , and avenues for self-advocacy.[219.1] The personal experiences of individuals living with RA are instrumental in shaping the development of support programs and resources within the community. Qualitative studies have highlighted the importance of understanding these experiences to improve clinical care and training.[239.1] Furthermore, integrating patient feedback into advocacy efforts ensures that the needs of patients are prioritized in policy discussions.[240.1] Moreover, the integration of psychological interventions into rheumatology care is increasingly recognized as essential for addressing the psychosocial aspects of living with RA. Collaborative care models that include mental health professionals can enhance treatment adherence and coping strategies, ultimately improving the quality of life for patients.[244.1] This multidisciplinary approach underscores the importance of addressing both the physical and emotional needs of individuals with RA, thereby fostering a more holistic treatment paradigm.

In this section:

Sources:

Impact On Quality Of Life

Physical and Emotional Effects

Rheumatoid arthritis (RA) significantly impacts both the physical and emotional well-being of patients, leading to a reduced health-related quality of life (HRQoL). The chronic nature of RA is associated with persistent pain, disability, and increased if not adequately treated, making quality-of- crucial in the absence of a cure for the disease.[248.1] Patients with RA often report diminished quality of life across various domains, including physical health, independence, and personal beliefs, when compared to the general population.[249.1] The assessment of HRQoL in RA patients has become increasingly common in clinical practice, with tools such as the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) being widely utilized.[247.1] Psychological factors also play a significant role in the overall quality of life for these patients. Anxiety and depression are prevalent among individuals with RA, contributing to increased pain, fatigue, and physical disability, which further exacerbate the decline in HRQoL.[252.1] Interventions aimed at improving the psychological aspects of living with RA have shown promise. For instance, patient education programs and psychological treatments, including cognitive behavioral therapy, can enhance coping strategies and overall well-being.[253.1] A multidisciplinary approach that integrates mental health services is essential for addressing the psychosocial aspects of RA management, providing holistic support to patients.[254.1] Moreover, comprehensive programs have been found to positively influence both pain perception and quality of life, particularly in patients with moderate to high disease activity.[262.1] Early diagnosis and treatment strategies, such as the treat-to-target approach, have also been associated with improved long-term outcomes in HRQoL, demonstrating the importance of timely intervention.[263.1] Overall, the interplay between physical symptoms and emotional health underscores the necessity for a comprehensive approach to managing rheumatoid arthritis, focusing on both physical and psychological well-being.

In this section:

Sources:

References

who.int favicon

who

https://www.who.int/news-room/fact-sheets/detail/Rheumatoid-arthritis

[4] Rheumatoid arthritis - World Health Organization (WHO) While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected (3). Overview. Rheumatoid arthritis (RA) is a chronic disease that causes inflammation around the body and commonly presents with pain in the joints.

cdc.gov favicon

cdc

https://www.cdc.gov/arthritis/rheumatoid-arthritis/index.html

[5] Rheumatoid Arthritis | Arthritis | CDC - Centers for Disease Control ... Basics Risk Factors Physical Activity and Arthritis Caring for Yourself Osteoarthritis Rheumatoid Arthritis Gout Fibromyalgia View All Rheumatoid arthritis (RA) causes pain, swelling, and stiffness in the joints. It’s best to diagnose and treat RA early to avoid joint damage and worsening symptoms and complications. Doctors diagnose RA through a physical exam, X-rays, lab tests, and a review of a patient’s health history. RA can be managed Smoking can also make it harder to be physically active, which is important for managing arthritis symptoms. Learn about other self-care strategies for arthritis, including RA, that can help you feel better.

who.int favicon

who

https://www.who.int/news-room/fact-sheets/detail/Rheumatoid-arthritis

[6] Rheumatoid arthritis - World Health Organization (WHO) While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected (3). ... Overview. Rheumatoid arthritis (RA) is a chronic disease that causes inflammation around the body and commonly presents with pain in the joints

mindovix.com favicon

mindovix

https://mindovix.com/articles/understanding-arthritis-rheumatoid-vs-other-types/

[22] Understanding Arthritis: Rheumatoid vs Other Types Comparative Symptoms with Other Types. Understanding the comparative symptoms of rheumatoid arthritis in relation to other types of arthritis is essential for accurate diagnosis and treatment. For instance, osteoarthritis (OA) often features pain linked with physical activity and wear on the joints, whereas RA pain can exist even while at rest.

verywellhealth.com favicon

verywellhealth

https://www.verywellhealth.com/rheumatoid-arthritis-symptoms-8391426

[24] Rheumatoid Arthritis Signs and Symptoms: Early and Late Stage Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the joints but can also affect other body areas, including the skin, eyes, lungs, heart, and nerves. RA shares many symptoms with other conditions, including joint infections, inflammatory diseases, other autoimmune diseases, and other types of arthritis. Stage 1 or early RA: In this stage, you will experience the earliest symptoms, such as morning stiffness and pain in the small joints of the hands and feet. Early symptoms of RA include fatigue, low-grade fever, weight loss, loss of appetite, malaise, and mild joint pain and stiffness. Treating RA is vital to reduce the potential for joint damage and more severe symptoms, like skin rash, rheumatoid vasculitis, eye inflammation, and lung or heart problems.

verywellhealth.com favicon

verywellhealth

https://www.verywellhealth.com/early-symptoms-of-rheumatoid-arthritis-5201856

[26] Early Stage Rheumatoid Arthritis in the Hands and Feet - Verywell Health In the early stages of rheumatoid arthritis (RA), people may first notice tenderness, stiffness, and pain in the small joints in the hands and feet. Rheumatoid arthritis (RA) is a type of inflammatory arthritis that primarily affects the joints of the hands, wrists, and knees, but any joint in the body can be affected. Beyond early-stage rheumatoid arthritis in the hands, some people experience RA that can damage other body systems, including the skin, eyes, heart, and blood vessels. People may have more than one joint affected in early RA but arthritis that affects four or more joints (polyarthritis) may progress. Apart from closely following your treatment plan for early-stage rheumatoid arthritis in your hands (or other RA symptoms), you can:

medicalnewstoday.com favicon

medicalnewstoday

https://www.medicalnewstoday.com/articles/rheumatoid-arthritis-history

[44] Rheumatoid arthritis history: Discovery and development The history of rheumatoid arthritis (RA) goes back hundreds of years. French physicians studied the condition that would become known as RA in the 19th centuryTrusted Source, learning more about it and trying early treatments, such as cold therapy and hot water baths. Keep reading to learn more about RA history, including its discovery, early treatment, research, and origins. It describes joint inflammation (arthritis) that resembles rheumatism (rheumatoid), an old medical term for joint pain and swelling. Rheumatoid arthritis history shows that treatment has come a long way since physicians first described the condition in the 19th century. https://www.niams.nih.gov/health-topics/rheumatoid-arthritis/diagnosis-treatment-and-steps-to-take Research into rheumatoid arthritis (RA) treatment is ever-evolving. Rheumatoid arthritis (RA): Outlook Rheumatoid arthritis (RA) is a chronic condition.

the-rheumatologist.org favicon

the-rheumatologist

https://www.the-rheumatologist.org/article/why-did-rheumatoid-arthritis-begin-in-1800/

[46] Why Did Rheumatoid Arthritis Begin in 1800? - The Rheumatologist The term "rheumatoid arthritis" was introduced by Garrod in 1859. 3,4 Watson, Buchanan, and Murdoch speculated further that RA, this new disease in history, was still evolving and would disappear perhaps by end of this century. 5 Indeed, these intriguing essays provoked efforts to identify earlier examples of RA in art, literature, history

rheumatic.theclinics.com favicon

theclinics

https://www.rheumatic.theclinics.com/article/S0889-857X(12

[49] Evolution of Classification Criteria for Rheumatoid Arthritis: How Do ... Classification criteria are created in an attempt to produce a homogenous group of subjects with rheumatoid arthritis (RA) who can be used for clinical and basic research. The 1987 revised criteria lead to improved performance and more confidence in correct classification compared with the 1958 criteria. As therapies were introduced and early, aggressive approaches to RA management became

mdcalc.com favicon

mdcalc

https://www.mdcalc.com/calc/10092/acr-eular-2010-rheumatoid-arthritis-classification-criteria

[50] ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria - MDCalc The ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria diagnoses rheumatoid arthritis (RA) in patients with undifferentiated inflammatory synovitis. Calc Function Diagnosis

sciencedirect.com favicon

sciencedirect

https://www.sciencedirect.com/science/article/pii/S0896841114000304

[51] Diagnosis and classification of rheumatoid arthritis History. As many chronic diseases, the history of rheumatoid arthritis started around 1500 BC when Ebers Papyruralies describe a condition similar to rheumatoid arthritis. ... 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum, 62

researchgate.net favicon

researchgate

https://www.researchgate.net/publication/356823689_Alfred_Baring_Garrod_and_the_beginnings_of_modern_rheumatology

[57] Alfred Baring Garrod and the beginnings of modern rheumatology Sir Alfred Baring Garrod coined the term rheumatoid arthritis in 1858. The British Ministry of Health adopted this term in 1922, and the American Rheumatism Association replaced atrophic arthritis

news-medical.net favicon

news-medical

https://www.news-medical.net/health/Rheumatoid-Arthritis-History.aspx

[60] Rheumatoid Arthritis History - News-Medical.net History of treatment of rheumatoid arthritis. In the olden days treatments for rheumatoid arthritis included bloodletting and leeching. In the Far East developed practises of acupuncture

the-rheumatologist.org favicon

the-rheumatologist

https://www.the-rheumatologist.org/article/a-short-history-of-ra-therapeutics/

[61] A Short History of Rheumatoid Arthritis Therapeutics In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion

arthritis.org favicon

arthritis

https://www.arthritis.org/science/impact/funded-research-timeline

[62] Historical Research - Arthritis Foundation In the 1950s and 60s, doctors began using an older form of this drug at lower doses to treat psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA). The older form of this drug was hard to manufacture, so a newer form was created. The newer form of this drug has been part of rheumatoid arthritis (RA) treatment for at least three decades.

medicalnewstoday.com favicon

medicalnewstoday

https://www.medicalnewstoday.com/articles/rheumatoid-arthritis-history

[64] Rheumatoid arthritis history: Discovery and development The history of rheumatoid arthritis (RA) goes back hundreds of years. French physicians studied the condition that would become known as RA in the 19th centuryTrusted Source, learning more about it and trying early treatments, such as cold therapy and hot water baths. Keep reading to learn more about RA history, including its discovery, early treatment, research, and origins. It describes joint inflammation (arthritis) that resembles rheumatism (rheumatoid), an old medical term for joint pain and swelling. Rheumatoid arthritis history shows that treatment has come a long way since physicians first described the condition in the 19th century. https://www.niams.nih.gov/health-topics/rheumatoid-arthritis/diagnosis-treatment-and-steps-to-take Research into rheumatoid arthritis (RA) treatment is ever-evolving. Rheumatoid arthritis (RA): Outlook Rheumatoid arthritis (RA) is a chronic condition.

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/31196652/

[66] The Natural History of Rheumatoid Arthritis - PubMed Purpose: This article reviews the phases of rheumatoid arthritis (RA) development in terms of the evolution of disease, with a focus on events that occur before the first appearance of clinically apparent inflammatory arthritis. This presynovitis period is defined in individuals who eventually develop classified RA as the pre-RA phase. We include additional discussion of the relevance of this

sciencedirect.com favicon

sciencedirect

https://www.sciencedirect.com/science/article/pii/S0149291819301924

[67] The Natural History of Rheumatoid Arthritis - ScienceDirect However, there is now established and evolving research that supports the conclusion that RA-related autoimmunity and inflammation are present long before the first onset of IA during a period that can be termed pre-RA. 3 These observations have generated a new understanding of how and when RA-related autoimmunity develops. In particular, these discoveries have raised interest in RA as a

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC11592031/

[88] Unlocking the Future: New Biologic Therapies for Rheumatoid Arthritis The advent of biologic therapies that target specific immune system components (e.g., cytokines, T cells) has transformed RA treatment by offering new management options. Keywords: biologic therapy, disease-modifying antirheumatic drugs (dmards), gene therapy, interleukin blockers, rheumatoid arthritis (ra), tnf inhibitors Unlike traditional DMARDs, biologic DMARDs specifically target immune system cells or proteins involved in the inflammatory process, effectively preventing the chronic destruction of synovial and other tissues caused by RA. In the present review, we discuss the potential of emerging RA biologic therapy centered on RASF (rheumatoid arthritis synovial fibroblasts) triggering molecules, B cell activating factor (BAFF), a protein of the tumor necrosis factor (TNF) family, and alarmins S100 calcium-binding protein A7 (S100A7, also known as psoriasin) and IL-36α in the pathogenesis of RA.

openaccessjournals.com favicon

openaccessjournals

https://www.openaccessjournals.com/articles/advances-in-biologic-therapies-for-rheumatoid-arthritis-a-review-of-recent-developments-17856.html

[90] Advances in Biologic Therapies for Rheumatoid Arthritis: A Review These advances reflect a deeper understanding of RA pathogenesis and a more targeted approach to treatment. Biologic therapies have proven to be effective in improving patient outcomes, including symptom relief, functional improvement, and reduction in joint damage.

bmj.com favicon

bmj

https://www.bmj.com/content/384/bmj-2022-070856

[91] Therapeutic advances in rheumatoid arthritis - The BMJ In addition, and reinforcing the view of rheumatoid arthritis as a disease of adaptive immune dysregulation, the B cell depleting chimeric mouse/human anti-CD20 monoclonal antibody rituximab, as well as the human cytotoxic T lymphocyte antigen 4 (CTLA4)-IgG1Fc fusion protein abatacept (which, in binding CD80/86 in preference to CD28, blocks co-stimulation to attenuate T cell activation) have both found roles in the clinic; the former is now largely reserved for patients who have had an inadequate response to a TNF inhibitor. . Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Therapeutic advances in rheumatoid arthritis BMJ 2024; 384 :e070856 doi:10.1136/bmj-2022-070856

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC8709568/

[92] Recent progress in treatments of rheumatoid arthritis: an overview of ... Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damage and physical dysfunction. Phase III international clinical trials have demonstrated that the clinical and structural effects of these JAK inhibitors were significantly more robust and rapid than the effects of placebo in MTX-naïve patients, as well as in RA patients with inadequate responses to csDMARDs such as MTX or bDMARDs such as TNF-targeting drugs [26–31]. [DOI] [PMC free article] [PubMed] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arthritis%20Rheumtol&title=Safety%20and%20biological%20activity%20of%20Rozibafusp%20Alfa%20in%20subjects%20with%20rheumatoid%20arthritis:%20final%20results%20of%20a%20phase%201b%20randomized,%20double-blind,%20placebo-controlled,%20multiple%20ascending%20dose%20study%20%5Babstract%5D&volume=72(Suppl%2010&publication_year=2020&pmid=35899378&doi=10.1002/acr2.11487&)] Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC4060201/

[109] Moving towards personalized medicine in rheumatoid arthritis Abstract To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this approach is to discover subgroups of patients that are characterized by a good or poor treatment outcome.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC11110814/

[110] Towards Personalized Medicine in Rheumatoid Arthritis - PMC Future of Personalized Medicine in Rheumatoid Arthritis Over recent years, advancement of methodologies and substantial investment has led to an explosion of promising potential biomarkers for treatment response in RA.

ncbi.nlm.nih.gov favicon

nih

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090026/

[111] Personalized medicine in rheumatology - PMC Early diagnosis of rheumatoid arthritis is significant in so much as the primary treatment can be started better. Pharmacogenetic and pharmacogenomic studies, which help determine the genetic profile of individual patients, may bring us closer to personalized medicine.

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/17922665/

[112] Personalized medicine in rheumatoid arthritis: hopes and ... - PubMed Multiple markers of treatment response have been analyzed in RA, but many of the studies are small and retrospective in nature. There are many obstacles to personalized medicine for RA patients, including incomplete understanding of disease pathogenesis, effecting changes in physician behavior, and acceptance of costs by health insurers.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC8709568/

[119] Recent progress in treatments of rheumatoid arthritis: an overview of ... Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damage and physical dysfunction. Phase III international clinical trials have demonstrated that the clinical and structural effects of these JAK inhibitors were significantly more robust and rapid than the effects of placebo in MTX-naïve patients, as well as in RA patients with inadequate responses to csDMARDs such as MTX or bDMARDs such as TNF-targeting drugs [26–31]. [DOI] [PMC free article] [PubMed] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arthritis%20Rheumtol&title=Safety%20and%20biological%20activity%20of%20Rozibafusp%20Alfa%20in%20subjects%20with%20rheumatoid%20arthritis:%20final%20results%20of%20a%20phase%201b%20randomized,%20double-blind,%20placebo-controlled,%20multiple%20ascending%20dose%20study%20%5Babstract%5D&volume=72(Suppl%2010&publication_year=2020&pmid=35899378&doi=10.1002/acr2.11487&)] Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC11592031/

[120] Unlocking the Future: New Biologic Therapies for Rheumatoid Arthritis The advent of biologic therapies that target specific immune system components (e.g., cytokines, T cells) has transformed RA treatment by offering new management options. Keywords: biologic therapy, disease-modifying antirheumatic drugs (dmards), gene therapy, interleukin blockers, rheumatoid arthritis (ra), tnf inhibitors Unlike traditional DMARDs, biologic DMARDs specifically target immune system cells or proteins involved in the inflammatory process, effectively preventing the chronic destruction of synovial and other tissues caused by RA. In the present review, we discuss the potential of emerging RA biologic therapy centered on RASF (rheumatoid arthritis synovial fibroblasts) triggering molecules, B cell activating factor (BAFF), a protein of the tumor necrosis factor (TNF) family, and alarmins S100 calcium-binding protein A7 (S100A7, also known as psoriasin) and IL-36α in the pathogenesis of RA.

sciencedirect.com favicon

sciencedirect

https://www.sciencedirect.com/science/article/pii/S1521694225000063

[121] What's new on the horizon for rheumatoid arthritis management Over the past several decades, as the understanding of RA pathogenesis has improved, new molecular targets for disease management have been discovered, resulting in a therapeutic revolution and the continuing development of targeted therapies.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC3383485/

[122] Understanding Personalized Medicine in Rheumatoid Arthritis: A ... Personalized medicine refers to the utilization of technologies at the molecular level to understand disease processes and improve health outcomes. ... We envision that the treatment of RA will not only include newer and more targeted agents but be truly personalized, based on the individual genetic, environmental and socioeconomic features

cell.com favicon

cell

https://www.cell.com/heliyon/fulltext/S2405-8440(24

[123] From molecular subgroups to molecular targeted therapy in rheumatoid ... Rheumatoid Arthritis (RA) is a heterogeneous autoimmune disease with multiple unidentified pathogenic factors. The inconsistency between molecular subgroups poses challenges for early diagnosis and personalized treatment strategies. In this study, we aimed to accurately distinguish RA patients at the transcriptome level using bioinformatics methods.

rheumatoidarthritis.org favicon

rheumatoidarthritis

https://www.rheumatoidarthritis.org/ra/diagnosis/index.html

[124] RA Diagnosis: What Criteria are used to Diagnose Rheumatoid Arthritis? If a patient is showing early signs and symptoms of RA, a doctor can refer the patient to a rheumatologist – a physician who specializes in arthritis and other diseases of the joints, muscles and bones. The patient’s medical history and family history are important factors in helping to reach a RA diagnosis. Some doctors take a more symptom based approach to diagnosing RA while others rely on blood tests and medical history to confirm a RA diagnosis. If a patient displays all the symptoms of RA and tests positive for antibodies then they can be diagnosed with seropositive RA. However, if a patient displays all the symptoms of RA, but doesn’t test positive for antibodies, the doctors can make a seronegative RA diagnosis.

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/38240831/

[134] Rheumatoid arthritis - PubMed We will discuss the clinical manifestations of rheumatoid arthritis, classification criteria, and the value of imaging in the diagnosis of the disease. The advent of new medications and the accumulated scientific evidence demand continuous updating regarding the diagnosis and management, including therapy, of rheumatoid arthritis.

archivesofrheumatology.org favicon

archivesofrheumatology

https://www.archivesofrheumatology.org/full-text/383

[135] Diagnostic Accuracy of the 2002 EULAR Criteria for the Clinical ... The simultaneous identification of all three criteria is optimal for the prediction of RA in patients with "early arthritis" because it raises the diagnostic accuracy of criteria to 80.9%. The new 2010 ACR/EULAR classification criteria can be useful for the identification of patients with "definite RA" and the initiation of therapy with

ard.bmj.com favicon

bmj

https://ard.bmj.com/content/80/9/1242

[136] Challenges in the diagnosis of early rheumatoid arthritis in times of ... Challenges in the provision of care and patients' reluctance to access healthcare services and adhere to drug prescriptions in course of COVID-19 pandemic undermine the fundamental principles of early diagnosis and treat to target, which have revolutionised the natural history of many chronic inflammatory diseases starting from rheumatoid arthritis (RA).1 Although most rheumatologists have

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC2964864/

[141] Anti-CCP Revised Criteria for the Classification of Rheumatoid ... In early inflammatory arthritis, the specificity of anti-CCP antibody for rheumatoid arthritis has ranged from 90-97%, compared to RF, which ranges from 80-90% [17, 21-23]. While the sensitivity of anti-CCP antibodies in early RA is comparable to that of RF, the detection of either RF or anti-CCP has significantly improved sensitivity for RA

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC8968629/

[155] The Effects of Patient Education on Psychological Status and Clinical ... The positive effect of patient education may be closely related to the active participation of patients, and it is very important for patients to adhere to rheumatoid arthritis-related interventions. However, our study found that patient education did not significantly improve anxiety, depression, pain, and CRP in patients with rheumatoid

ard.eular.org favicon

eular

https://ard.eular.org/article/S0003-4967(24

[156] Effects of needs-based patient education on self-efficacy and health ... The Educational Needs Assessment Tool (ENAT) is a self-completed questionnaire, which allows patients with arthritis to prioritise their educational needs. The aim of this study was to evaluate the effects of needs-based patient education on self-efficacy, health outcomes and patient knowledge in people with rheumatoid arthritis (RA).

creakyjoints.org favicon

creakyjoints

https://creakyjoints.org/about-arthritis/rheumatoid-arthritis/ra-patient-perspectives/guadalupe-torres-rheumatoid-arthritis-became-comfortable-with-advocacy/

[158] How Rheumatoid Arthritis Patient Guadalupe Torres Became an Advocate From 'Disengaged' to Fighting for Change: The Research Project That Pushed Rheumatoid Arthritis Patient Guadalupe Torres to Become an Advocate PUBLISHED 11/03/21 BY Leah Rocketto When she was diagnosed with rheumatoid arthritis (RA) at 16, Guadalupe Torres faced linguistic and cultural barriers that impacted the way she viewed the health

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC8205440/

[160] Biomarkers in Rheumatoid Arthritis - PMC - PubMed Central (PMC) The utilization and identification of biomarkers in rheumatoid arthritis (RA) to facilitate timely diagnosis and the optimal management of the disease is an area of active investigation. This review focuses on the four biomarkers included in these criteria that are available for routine clinical use: rheumatoid factor, autoantibodies against citrullinated proteins, erythrocyte sedimentation rate, and C-reactive protein; the multi-biomarker disease activity test is also discussed. ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; RF, rheumatoid factor; anti-CCP2, anti-cyclic citrullinated peptide2; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; MBDA, multi-biomarker disease activity test; DAS28, Disease Activity Score 28; SDAI, Simplified Disease Activity Index 46.Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.

openaccessjournals.com favicon

openaccessjournals

https://www.openaccessjournals.com/articles/biomarkers-in-rheumatoid-arthritis-enhancing-diagnosis-and-predicting-treatment-responses.pdf

[161] PDF diagnosis and management of rheumatoid arthritis. From improving early detection to predicting treatment responses, biomarkers offer a wealth of opportunities to enhance patient care and outcomes. While traditional biomarkers such as RF and ACPA remain cornerstone tools in RA diagnosis, the discovery of new biomarkers

sciencedirect.com favicon

sciencedirect

https://www.sciencedirect.com/science/article/pii/S0165247817302079

[163] Biomarkers for rheumatoid arthritis: From molecular processes to ... RF is one of the most widely used biomarkers in establishing RA diagnosis , even though negative result does not rule out RA, and positive results can be due to other diseases. RF also occurs in several other systemic autoimmune diseases, such as Sjögren's syndrome (75-95%), mixed cryoglobulinemia (monoclonal RF, 100%), systemic lupus

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC10775516/

[164] Management and treatment outcomes of rheumatoid arthritis in the era of ... Background. Advances in rheumatoid arthritis (RA) treatment, highlighted by biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs), have altered the paradigm of RA treatment in the last decade. ... Treatment options for rheumatoid arthritis (RA) have progressed over the past two decades. Methotrexate

arthritis.org favicon

arthritis

https://www.arthritis.org/health-wellness/treatment/treatment-plan/disease-management/treatments-for-rheumatoid-arthritis

[165] Treatments for Rheumatoid Arthritis About Arthritis More About Arthritis Treatments for Rheumatoid Arthritis Learn what medical treatments are available for RA and what you can do to manage your disease. Getting control of rheumatoid arthritis (RA) and the inflammation that fuels it involves medication, physical activity and living a healthy lifestyle. Massage can help reduce pain, improve joint function and ease stress and anxiety. Read about the recommended therapies for RA, including various types of medications, how your doctor may approach your treatment, and what to discuss with your health care provider. Rheumatoid arthritis is an inflammatory type of arthritis that can cause joint pain, swelling and damage. Live your best with RA by connecting with local experts and meeting others with RA who can help.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC10628871/

[166] Overview of Rheumatoid Arthritis and Scientific Understanding of the ... These may be used alone but are often given in combination with other medications such as NSAIDs. Use of TNF-α inhibitors have revolutionised the era of RA treatment options resulting in the expansion of further biological DMARDs.96 Anti TNF-α drugs such as infliximab (IFX), etanercept (ETN), adalimumab (ADA), golimumab (GOLI), and certolizumab pegol (CZP) have been extensively used as treatment options.97 Canakinumab is one such anti-IL-1β drug developed to cure the disease.98,99 Several other anti-interleukin monoclonal antibodies used in the management of RA are, Olokizumab, Sirukumab, Tocilizumab, Sarilumab, Briakinumab, Ixekizumab.100 Over-the-counter (OTC) medications, complementary, and alternative treatments such as herbal and indigenous medicines can also be helpful to relieve pain and reduce inflammation in RA patients.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC6422329/

[167] Rheumatoid Arthritis: A Brief Overview of the Treatment - PMC Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. Rheumatoid arthritis (RA) is a chronic, symmetrical, inflammatory autoimmune disease that initially affects small joints, progressing to larger joints, and eventually the skin, eyes, heart, kidneys, and lungs. Biologics, also known as biological DMARDs, are rapidly effective in retarding the progression of the joint damage caused by RA. However, a 2010 study showed decreased rates of joint surgery in RA patients 40–59 years of age. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Treatment with Biologicals in Rheumatoid Arthritis: an Overview. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007.

healthline.com favicon

healthline

https://www.healthline.com/health/rheumatoid-arthritis/rheumatoid-arthritis-treatment

[168] Rheumatoid Arthritis Treatment: Medications and More - Healthline Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain and inflammation. The condition is chronic, and there's no cure. However, in recent years, new treatment options have

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC1395798/

[171] Pathway to Independence: Physical Therapy for Patients With Rheumatoid ... Rheumatoid arthritis (RA) is a serious, systemic, autoimmune disease that results in the inflammation of joints and joint lining and may also affect internal organs and vascular systems. ... Physical therapists are able to progressively tailor treatment plans to the individual by incorporating periods of activity and rest. Exercises that gently

enhance.physio favicon

enhance

https://enhance.physio/managing-rheumatoid-arthritis-with-physiotherapy/

[172] Managing Rheumatoid Arthritis With Physiotherapy Physiotherapy treatment for rheumatoid arthritis 1. Exercise therapy. Range of motion exercises: Gentle exercises to maintain or increase joint flexibility. Strengthening exercises: Targeted exercises to strengthen muscles surrounding the joints. Aerobic exercises: Low-impact activities like swimming, cycling, or water aerobics to improve aerobic capacity and cardiovascular health.

sciencedaily.com favicon

sciencedaily

https://www.sciencedaily.com/releases/2023/11/231108164206.htm

[176] Toward new targeted treatments for rheumatoid arthritis New research may lead to new targeted treatments for rheumatoid arthritis (RA), an autoimmune disease that causes joint inflammation and destruction. New research led by University of Colorado School of Medicine faculty members Fan Zhang, Ph.D., and Anna Helena Jonsson, M.D., Ph.D., may lead to new targeted treatments for rheumatoid arthritis (RA), an autoimmune disease that causes joint inflammation and destruction. Published today in the journal Nature, their findings reflect the work of dozens of researchers working together as members of the Accelerating Medicines Partnership: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP: RA/SLE) Network, including Michael Holers, M.D., professor of medicine and the site principal investigator at the CU School of Medicine.

arthritis-research.biomedcentral.com favicon

biomedcentral

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1266-4

[178] Poor prognostic factors guiding treatment decisions in rheumatoid ... Prognostic factors are used for treatment decisions in rheumatoid arthritis (RA). High disease activity, the early presence of erosions, and autoantibody positivity are the most frequently used poor prognostic factors but other features, such as functional disability, extraarticular disease, or multibiomarkers, are also assessed. Prognostic factors are incorporated in current treatment

openaccessjournals.com favicon

openaccessjournals

https://www.openaccessjournals.com/articles/the-role-of-diet-and-lifestyle-in-managing-rheumatoid-arthritis.pdf

[182] PDF cornerstone of rheumatoid arthritis management, diet and lifestyle changes play an increasingly important role in improving disease outcomes, reducing symptoms, and enhancing the overall quality of life for RA patients. The Mediterranean diet, omega-3 fatty acids, weight management, and regular physical activity can

nyulangone.org favicon

nyulangone

https://nyulangone.org/conditions/rheumatoid-arthritis/treatments/lifestyle-changes-for-rheumatoid-arthritis

[183] Lifestyle Changes for Rheumatoid Arthritis - NYU Langone Health Social Work & Care Management. ... Lifestyle Changes for Rheumatoid Arthritis. NYU Langone rheumatologists—doctors who specialize in conditions that cause painful swelling in joints and muscles—recommend making lifestyle changes to reduce pain and prevent joint damage.

nccih.nih.gov favicon

nih

https://www.nccih.nih.gov/health/tips/6-things-to-know-about-complementary-health-approaches-for-rheumatoid-arthritis

[186] 6 Things To Know About Complementary Health Approaches for Rheumatoid ... Some psychological or physical complementary health approaches—such as relaxation techniques, mindfulness meditation, tai chi, and yoga—may be beneficial additions to conventional treatment plans for rheumatoid arthritis.However, some studies indicate that these practices may do more to improve other aspects of patients' health than to relieve pain.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC6089679/

[190] Experience and context shape patient and clinician goals for treatment ... Patient and clinician goal alignment, central to effective patient-centered care, has been linked to improved patient experience and outcomes, but has not been explored in rheumatoid arthritis (RA). This study aimed to explore goal conceptualization among RA patients and clinicians.

sciencedirect.com favicon

sciencedirect

https://www.sciencedirect.com/science/article/abs/pii/S1521694224001037

[191] Physiotherapy and occupational therapy in rheumatoid arthritis ... It also addresses the role of these therapies in managing RA-related comorbidities, with an emphasis on exercise therapy, manual techniques, patient education and emerging digital interventions. Evidence supports the inclusion of tailored exercise regimens, such as cardiorespiratory training, resistance exercises and neuromotor activities, as

nursing.pitt.edu favicon

pitt

https://www.nursing.pitt.edu/sites/default/files/sample_etd_1.pdf

[202] PDF Rheumatoid arthritis (RA) is an autoimmune disease in which joint damage occurs when the ... management of RA is not curative, but can significantly reduce the progression of joint damage ... Social support networks are known to buffer disease-related distress and improve quality of life in patients with RA by enhancing their ability to cope

ncbi.nlm.nih.gov favicon

nih

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585913/

[215] Patient advocacy and arthritis: moving forward. - PMC The first patient advocacy groups for arthritis were set up over 20 years ago in the USA and have subsequently spread to many other countries. This paper discusses the growth and impact of personal advocacy as well as recent developments in group advocacy in the Asia-Pacific region, Europe, and North America, in terms of arthritis awareness

aiarthritis.org favicon

aiarthritis

https://www.aiarthritis.org/advocacy

[216] Advocacy for Autoimmune and Autoinflammatory Arthritis Learn about AiArthritis' advocacy efforts in public policy, research, and healthcare access for autoimmune and autoinflammatory arthritis patients. ... Rheumatoid Arthritis (RA) Psoriatic Arthritis (PsA) Systemic Lupus Erythematosus (SLE) Sjögren's Disease (SD) ... We impact policy and legislation through personal patient experiences

gafpa.org favicon

gafpa

https://gafpa.org/wp-content/uploads/2021/06/EAfPA_RA_Policy_Brief_Oct-2017.pdf

[217] PDF RHEUMATOID ARTHRITIS: ACCESS, POLICY AND ADVOCACY GOALS OCTOBER 2017. ... Rheumatoid arthritis (RA) is a painful autoimmune disease that creates ... Europe to have more timely, appropriate and effective access to treatment. Patient-Reported Outcomes By increasing awareness and fostering prompt action as described above, we can also strengthen

verywellhealth.com favicon

verywellhealth

https://www.verywellhealth.com/how-to-find-a-rheumatoid-arthritis-support-group-5204931

[218] Finding a Rheumatoid Arthritis Support Group - Verywell Health Healing Rheumatoid Arthritis Naturally Support Group is a Facebook community for people interested in alternative healing methods. Advice from the group revolves around diet, exercise, and stress management. ... Finding a rheumatoid arthritis support group can be overwhelming because there are many to choose from. The first step is deciding

arthritis.org favicon

arthritis

https://www.arthritis.org/rheumatoid-arthritis-patient-education

[219] Information for Rheumatoid Arthritis Patients - Arthritis Foundation The Arthritis Foundation website is home to valuable resources for rheumatoid arthritis patients. Connect with your community, and learn how to live healthy with arthritis. ... You'll find support from others living with RA, ways to stay active and manage your disease, opportunities to advocate for yourself and others - so you can say Yes

rheumatoidarthritis.org favicon

rheumatoidarthritis

https://www.rheumatoidarthritis.org/living-with-ra/exercise/index.html

[223] RA and Exercise: Does Exercise Help with Pain and Inflammation? As part of a well-rounded treatment strategy, it is important to include exercise for rheumatoid arthritis (RA). Though it may seem difficult or challenging to exercise, especially when dealing with chronic pain, physical activity is necessary to increase joint function, strengthen muscles, and improve overall health and energy levels. While…

rupahealth.com favicon

rupahealth

https://www.rupahealth.com/post/mental-health-and-rheumatoid-arthritis-coping-with-emotional-challenges

[225] Mental Health and Rheumatoid Arthritis: Coping with Emotional Challenges Managing mental health is essential for those living with RA, as it involves addressing both the physical and emotional aspects of the disease. Engage with mental health professionals who understand chronic illness to get personalized support and coping strategies for the emotional challenges of RA. Rheumatoid Arthritis (RA) impacts both physical and mental health, with pain, fatigue, and lifestyle changes often leading to anxiety, depression, and stress. Managing mental health is essential for those living with RA, as it involves addressing both the physical and emotional aspects of the disease. Rheumatoid Arthritis (RA) impacts both physical and mental health, with discomfort, fatigue, and lifestyle changes often leading to anxiety, depression, and stress.

rheumatologyadvisor.com favicon

rheumatologyadvisor

https://www.rheumatologyadvisor.com/features/rheumatologic-diseases-and-mood-disorders/

[227] Rheumatologic Diseases and Mood Disorders: Is Inflammation the Link? Patients with rheumatoid arthritis (RA) and other rheumatologic diseases are far more likely to experience mental health disorders, including anxiety and depression, compared with the general population. 1,2 Despite their high prevalence, such comorbidities are frequently underdiagnosed or misdiagnosed, which often leads to inadequate treatment

rupahealth.com favicon

rupahealth

https://www.rupahealth.com/post/mental-health-and-rheumatoid-arthritis-coping-with-emotional-challenges

[228] Mental Health and Rheumatoid Arthritis: Coping with Emotional Challenges Social isolation is another challenge for those with RA, as discomfort, fatigue, and mobility issues often lead to withdrawing from social activities. This can result in loneliness and disconnection, further affecting mental health and making it harder to maintain emotional well-being. Coping Strategies for Mental Health in Rheumatoid Arthritis

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/17175654/

[239] The personal impact of rheumatoid arthritis on patients' identity: a ... Objective: To provide a detailed understanding of the direct personal experiences of living with rheumatoid arthritis (RA) and the impact of the illness upon patients' lives, to inform the improvement of clinical care and training. Method: A qualitative study was performed using data from semi-structured interviews with 26 patients who live with RA, recruited at two outpatient clinics in south

aiarthritis.org favicon

aiarthritis

https://www.aiarthritis.org/advocacy

[240] Advocacy for Autoimmune and Autoinflammatory Arthritis We impact policy and legislation through personal patient experiences, collaborative support, and innovative programs that aim to increase the number of patients who have a voice in public policy. Everything we do at our organization is based on listening to our peers (patients and caregivers) and identifying what they say needs to happen to

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC10746866/

[244] Psychosocial Aspects of Rheumatic Disease Management: Addressing Mental ... Psychosocial Aspects of Rheumatic Disease Management: Addressing Mental Health and Well-Being - PMC A multidisciplinary approach integrating mental health services is pivotal for addressing the psychosocial aspects of rheumatic disease, offering a holistic perspective. The future of rheumatic disease management lies in a patient-centered, multidisciplinary approach that addresses both physical and mental aspects. Keywords: patient-centered care, multidisciplinary approach, treatment adherence, coping strategies, chronic pain, emotional burden, well-being, mental health, rheumatic disease, psychosocial A multidisciplinary approach to care is pivotal in effectively managing the psychosocial aspects of rheumatic disease and providing holistic support for patients . Overall, a multidisciplinary approach, illustrated by case studies and bolstered by the integration of mental health services, presents a promising avenue for addressing the intricate psychosocial aspects of rheumatic disease management.

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/24973898/

[247] The impact of rheumatoid arthritis on quality-of-life assessed using ... Objective: The assessment of health-related quality-of-life (HRQoL) in rheumatoid arthritis (RA) is becoming increasingly common in both research and clinical practice. One of the most widely used tools for measuring HRQoL is the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36).

pubmed.ncbi.nlm.nih.gov favicon

nih

https://pubmed.ncbi.nlm.nih.gov/18793031/

[248] Quality-of-life assessment in rheumatoid arthritis - PubMed Rheumatoid arthritis (RA) is a chronic and lifelong autoimmune disorder that results in significant pain, disability and excess mortality if untreated or inadequately treated. Quality-of-life (QOL) assessments are particularly important in the absence of a cure for RA. Generic and disease-specific p …

journals.sagepub.com favicon

sagepub

https://journals.sagepub.com/doi/10.1177/2050312117713647

[249] Quality of life in patients with established rheumatoid arthritis: A ... Patients with rheumatoid arthritis perceive reduced quality of life in several domains, such as physical health, level of independence, environment and personal beliefs, compared with the healthy population. There is an increasing interest in quality of life in clinical and medical interventions.

ncbi.nlm.nih.gov favicon

nih

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531278/

[252] Psychological affection in rheumatoid arthritis patients in relation to ... Rheumatoid arthritis (RA) is a common, systemic autoimmune disease characterized by persistent symmetric polyarthritis (synovitis). Anxiety and depression are common among patients with RA, compared to the general population and have been associated with increased pain, fatigue, physical disability and health care costs, and an overall reduced health-related quality of life.

ncbi.nlm.nih.gov favicon

nih

https://www.ncbi.nlm.nih.gov/books/NBK384460/

[253] Rheumatoid arthritis: Research summaries - Can psychological treatment ... Patient education programs, psychological treatment and cognitive behavioral therapy may help people with rheumatoid arthritis cope in everyday life. Different measures are often combined, such as relaxation techniques, stress management and strategies to avoid using up your energy levels and to optimize planning in daily life.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC10746866/

[254] Psychosocial Aspects of Rheumatic Disease Management: Addressing Mental ... Psychosocial Aspects of Rheumatic Disease Management: Addressing Mental Health and Well-Being - PMC A multidisciplinary approach integrating mental health services is pivotal for addressing the psychosocial aspects of rheumatic disease, offering a holistic perspective. The future of rheumatic disease management lies in a patient-centered, multidisciplinary approach that addresses both physical and mental aspects. Keywords: patient-centered care, multidisciplinary approach, treatment adherence, coping strategies, chronic pain, emotional burden, well-being, mental health, rheumatic disease, psychosocial A multidisciplinary approach to care is pivotal in effectively managing the psychosocial aspects of rheumatic disease and providing holistic support for patients . Overall, a multidisciplinary approach, illustrated by case studies and bolstered by the integration of mental health services, presents a promising avenue for addressing the intricate psychosocial aspects of rheumatic disease management.

pmc.ncbi.nlm.nih.gov favicon

nih

https://pmc.ncbi.nlm.nih.gov/articles/PMC7952341/

[262] Improving the quality of life of patients with rheumatoid arthritis ... Improving the quality of life of patients with rheumatoid arthritis after rehabilitation irrespective of the level of disease activity - PMC The aim of the study was to analyze the impact of a comprehensive rehabilitation on a subjective perception of pain and quality of life in patients with rheumatoid arthritis depending on the level of disease activity. In conclusion, the rehabilitation of patients with moderate to high disease activity is effective and the success of comprehensive rehabilitation is demonstrated by the decrease of the DAS28 score and the pain level reported by patients, as well as improving self-assessment of health and quality of life. The study attempts to analyze how a comprehensive rehabilitation affects pain and quality of life among patients with rheumatoid arthritis depending on the level of the disease activity.

academic.oup.com favicon

oup

https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keae212/7638805

[263] Long-term clinical outcomes in early rheumatoid arthritis that was ... Introduction. With the introduction of early treat-to-target strategies, clinical outcomes in people with RA significantly improved .In trials, functional outcomes and quality of life improved when a strict treat-to-target regimen was used .Radiographic damage was also shown to be limited with early treat-to-target therapy .In the BeSt study, after 10 years, most patients